Public Procurement of Medicines in Europe: Key Findings and Best Practices 

By HEOR Staff Writer

June 28, 2023

Experts in the Pharmacoeconomics Department recently conducted a study on the best practices in the public procurement of medicines. Commissioned by the European Commission, this study aims to improve access to medicines, affordability, availability, and more. 

Public procurement of medicines can improve access, foster competition, and address important policy objectives. This study mapped and analyzed PPM practices across 32 European countries, revealing some fascinating insights. 

 

 Findings include:

  • Different organizational forms of procurement, ranging from facility-based to centralized procurement.
  • Use of various procedures and techniques, including the Most Economically Advantageous Tender
  • Specific forms of procurement in the hospital sector
  • Impacts on policy objectives, such as access to medicines and environmental protection
  • Best practices for optimizing PPM in Europe

 

Discover the full report for a comprehensive understanding of PPM practices in Europe on the below link. Let’s work together to ensure affordable and accessible medicines for all! 

Reference url

Recent Posts

conditional adoption pathways endometriosis
Conditional Adoption Pathways for Endometriosis Diagnostics

By João L. Carapinha

July 8, 2026

The introduction of conditional adoption pathways for endometriosis offers a structured route to faster diagnosis for the millions of women facing four-to-ten-year delays within the NHS. N...
biologic dispensing implementation gaps
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

By João L. Carapinha

July 7, 2026

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...
curative therapy commercialization gap
Curative Therapy Commercialization Gap and Global Access Challenges

By João L. Carapinha

July 7, 2026

The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...